Cost-effectiveness and budget impact of long-acting risperidone in Portugal: A modeling exercise

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 349-358

  Heeg, Bart M S ^a   Antunes, J ^b   Figueira, M L ^c   Jara, J M ^d   Marques Teixeira, J ^e   Palha, A P ^f   Vaz Serra, A ^g   Buskens, E ^a   Caleo, S ^h   Gouveia Pinto, C ^i,j   Van Hout, B A ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b Janssen Cilag Farmacêutica ^*  (Portugal)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d Hospital Julio de Matos   (Portugal)

^e Centro Hospitalar Conde de Ferreira   (Portugal)

^f HOSPITAL DE SÃO JOÃO   (Portugal)

^g CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^h JANSSEN RESEARCH FOUNDATION   (Belgium)

ⁱ UNIVERSITY OF LISBON   (Portugal)

^j Research Center on the Portuguese Economy CISEP   (Portugal)

more..

Author keywords

Antipsychotic; Atypical; Conventional; Cost effectiveness; Long acting; Portugal; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE; HUMAN; OUTPATIENT; PATIENT COMPLIANCE; PORTUGAL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ANTIPSYCHOTIC AGENTS; BUDGETS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; HOSPITALIZATION; HUMANS; MODELS, ECONOMETRIC; OUTCOME ASSESSMENT (HEALTH CARE); PORTUGAL; PSYCHOLOGICAL TESTS; PSYCHOMETRICS; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RISPERIDONE; TIME FACTORS;

EID: 39749149634     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X253834     Document Type: Article

References (49)

1. Edwards N, Rupnow F, Pashos C, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics 2005;23:299-314
2. De Graeve D, Smet A, Mehnert A et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23:35-47
3. Laux G, Heeg BMS, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23:49-61
4. Chue PS, Heeg BMS, Buskens E, van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23:62-74
5. Urdahl H, Knapp M, Edgell ET, et al, on behalf of the SOHO study group. Unit costs in international economic evaluations: resource costing of the schizophrenia outpatient health outcomes study. Acta Psychiatr Scand 2003;107:S41-7
6. Lindgren P, Stenestrand U, Malmberg K, Jonsson B. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther 2005;27:100-110
7. International Monetary Fund. World Economic Outlook Database, July 2006. http://www.imf.org/external/pubs/ft/weo
8. da Silva E, Pinto C, Sampaio C, et al. Guidelines for economic drug evaluation studies. 1998. Infarmed
9. Sadock BJ, Sadock VA. Kaplan & Sadock's Pocket Handbook of Clinical Psychiatry, 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2001
10. Divided attention shared care; from problem areas to quality in the care of patients with schizophrenia. 2000. Schizophrenia Platform the Netherlands. 2000
11. Neeleman J. A continuum of premature death. Meta-analysis of competing mortality in the psychosocially vulnerable. Int J Epidemiol 2001;30:154-62
12. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
13. Tollefson GD, Beasly CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 2002;154:457-65
14. Carpenter W, Buchanan R. Schizophrenia. N Engl J Med 1994;330:681-90
15. McIntyre R, Trakas K, Lin D, et al., and CNOMSS Study Group. Risk of adverse events associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia (CNOMSS). 51st Annual Canadian Psychiatric Association Meeting, 2001, Montreal [Abstract]
16. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63
17. Csernansky J. Risperidone vs haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long-term double-blind comparison. Biol Psychiatry 2001;47:S31-2
18. Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors - a United States perspective. J Clin Psychiatry 1984;45:36-42
19. Health Care Insurance Board. Pharmacopoeia the Netherlands. Amstelveen: Health Care Insurance Board, 2002
20. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002;54:253-64
21. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2003. London, NICE
22. Dolder C, Lacro J, Dunn L, Jeste D. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8
23. Fleischhacker W, Oehl M, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64:S3-9
24. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6
25. Kay S. Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel, 1991
26. Wolthaus J, Dingemans P, Schene A, et al. Caregiver burden in recent-onset schizophrenia and spectrum disorders: the influence of symptoms and personality traits. J Nerv Ment Dis 2005;190:241-7
27. Cheung P, Schweitzer I, Crowley K, Tuckwell V. Violence in schizophrenia: role of hallucinations and delusions. Schizophr Res 1997;29:181-90
28. Steinert T, Wolfe M, Gebhardt R Measurement of violence during in-patient treatment and association with psychopathology. Acta Psychiatr Scand 2000;102:107-12
29. Infarmed.December 2003. Lisbon: Instituto Nacional da Farmácia e do Medicamento. http:/www.Infarmed.pt
30. Ordem dos Médicos. Código Allianz de Nomenclatura e Valor Relativo. de Actos Médicos. 2003
31. Mahmoud R, Engelhart L, Janagap C, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder; symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:275-86
32. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 1997;68:377-92
33. Arango C, Calcedo Barba A, et al. Violence in inpatients with schizophrenia: a prospective study. Schizophr Bull 1999;25:493-503
34. Cheung P, Schweitzer I, Crowley K, Tuckwell V. Aggressive behaviour in schizophrenia: the role of psychopathology. Aust N Z J Psychiatry 1997;1:62-7
35. Shaw J. Assessing the risk of violence in patients. BMJ 2000;320:1088-9
36. Hodgins S, Muller-Isberner. Preventing crime by people with schizophrenic disorders: the role of psychiatric services. Br J Psychiatry 2004;185:245-50
37. Chue P, Devos E, Duchesne I, Leal A, Mehnert A. Hospitalisation rates in patients during long-term treatment with long-acting risperidone injection. Int J Clin Neuropsychopharmacol 2005;5:S128-9
38. Remington G, Adams M. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40:S5-11
39. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-17
40. Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000;29:1-9
41. Health Care Insurance Board. Farmacotherapeutisch Kompas 2002. 2002. Amstelveen, Health Care Insurance Board
42. Ministério da Saúde. Portaria 132/2003 de 5 de Fevereiro. Diário da República, I Série-B, n.30, 2003
43. McMurran M. Dual diagnosis of mental disorder and substance misuse. 2002. NHS
44. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28:43-61
45. Goldner E, Hsu L, Waraich P, Somers J. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002;47:833-43
46. Selten J, Veen N, Feller W, et al. Incidence of psychotic disorders in immigrant groups to the Netherlands. Br J Psychiatry 2001;178:367-72
47. Grinspoon L, et al. Schizoaffective disorder. The Harvard Mental Health Lett 1996;13:1-4
48. Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23:17-33
49. Eriksson L, Almqvist A, Mehnert A, Eriksson B. Reduction in need for institutional care in chronic schizophrenia subjects switched to long-acting risperidone. 45th Annual and 4th Mediterranean meeting of the Scandinavian college of Neuro-Psychophamacology. Juan-les-Pins [Abstract]